IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer

YANG Mei; SHEN Bo

doi:10.12019/j.issn.1671-5144.2021.02.002

YANG Mei, SHEN Bo. IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002

Citation:

YANG Mei, SHEN Bo. IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002

Citation:

YANG Mei, SHEN Bo. IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 71-75. DOI: 10.12019/j.issn.1671-5144.2021.02.002

IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer

YANG Mei,
SHEN Bo

Graphical Abstract

Abstract

FullText(HTML)

References (7)

IMpassion130: The Efficacy of Atezolizumab Plus Nab-Paclitaxel Treatment in Comparison With Nab-Paclitaxel Alone as First-Line Treatment of Advanced Triple-Negative Breast Cancer

Catalog

Export File

Citation

Format

Content